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Abstract
Genetics and epigenetics studies have been used widely for psychiatric and be-
havior disorders such as substance use and Autism Spectrum Disorders(ASD). By
utilizing genetics on ASD and epigenetics data on injection drug use(IDU) from the
Department of Mental Health, we are able to identify genetic or epigenetic region
of interests. In Aim 1 and Aim 2, we used an ongoing longitudinal data called the
AIDS Linked to the Intravenous Experience (ALIVE) study, and it contained past
six month IDU phenotypic data and epigenetics data from peripheral blood on 2-4
visits from 288 subjects. Taking advantage of the longitudinal design, we conducted
four separate epigenome-wide association analyses(EWAS) on past six month any
injection drug use, heroin only injection use, cocaine only injection use, and co-use
of heroin and cocaine injection. To borrow information across these four separate
EWASs based on correlated phenotypes, we modified the correlation motif method
and applied it into epigenetics data, and the top hits after joint analyses by correla-
tion motif are now epigenome-wide significant after adjusting for multiple comparison.
The epigenetic marker near the FKBP5 gene was found to be associated with IDU,
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which is also a gene of interest for other types of psychiatric disorders. In the ALIVE
study, we also conducted EWAS on HIV, and used PCs that are negatively associ-
ated with CD4+ cells and positively associated with CD8+ cells to account for cell
composition difference between chronic HIV infected individuals and HIV negative in-
dividuals. We discovered a epigenome-wide significant methylation site near NLRC5
gene, which is also reported in an independent EWAS study on HIV. In another ge-
netic study called the Study to Explore Early Development (SEED), we have ASD
phenotypic information and genetics information on about 1200 cases and controls.
We utilized brain expression quantitative loci(brain eQTLs) from public literature
to extract brain eQTL single nucleotide polymorphism(brain eSNPs) to reduce the
search space from genome-wide variation to only brain expression related SNPs. We
discovered that only temporal cortex eSNPs shows qqplots that is of suggestive asso-
ciation, and other brain region eSNPs are significantly deflated. This finding confirms
with other imaging studies on temporal cortex might be affected by ASD.
Primary Reader: Brion Maher
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1.1.1 Why mental health and psychiatric genetics?
The prevalence of mental disorders and global burden has often been underesti-
mated. The lifetime prevalence of common mental disorders is 29.2% (25.9-32.6%)
according to a meta analysis from 1980-2013.3 In the US, about half of the sample
in a nationally representative survey met lifetime diagnostic criteria for a mental dis-
order.4 In addition to the high prevalence of mental disorder, the economic cost and
burden is substantial,5 including disability, premature mortality, burden to caregiver,
etc. Recent research has argued that the true burden of mental illness is underesti-
mated, and the global burden of mental disorders ranks first among all physical and
1
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mental illness in terms of years lived with disability.6
Despite the high prevalence and tremendous burden to patients, patient’s families
and the society, the underlying biological mechanism of most mental disorders remains
mostly unknown. For example, in Autism Spectrum Disorder (ASD), the current
treatment options are limited to relieving symptoms but cannot fully cure the disease.7
Another challenge is that the diagnosis of mental disorders is more complicated than
physical illness. Unlike type 2 diabetes and heart diseases, there rarely exist valid
biomarkers as valid measures for mental disorders.
The current challenges in understanding mental health disorders and treatment
reflects our lack of knowledge of the brain. The brain plays the most important
role in our body since it acts as the central processing unit to regulate our body in
response to environmental changes. It is also the most complex tissue to study and
most difficult tissue to obtain from humans. It is not surprising that unlike diseases
affecting other tissues, there have been fewer advances in disorders related to brain.
However, the current advances in genetic tools open a window to study brain
related genes. The genotyping technology has been improved dramatically during
the past decade, and the cost is greatly lowered, leading to numerous genetics studies
on large populations. Genetics studies are very important to mental health research
since it has been long observed that some mental disorders aggregate in families and
genes may be involved in many mental disorders. Since the etiology of most mental
disorders remains unknown, genetics studies provide a method to pinpoint proteins
2
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and enzymes encoded in the genome that implicate specific biological pathways.
The Department of Mental Health in Johns Hopkins Bloomberg School of Public
Health provides great opportunities to study the genetics and epigenetics of mental
health disorders, and there are two great sources of genetics and epigenetics data on
substance use from Dr. Brion Maher and Autism Spectrum Disorders from Dr. Dani
Fallin. I’m more than honored to have the opportunity to learn to analyze these
valuable data and contribute to our collective knowledge on the etiology of mental
disorders.
The following background section will provide background knowledge on gen-
eral genetics and epigenetics tool used in psychiatric genetics, epidemiology and ge-
netic/epigenetic advances in injection drug use and autism spectrum disorder.
1.1.2 Genetics and epigenetics approaches in men-
tal health
1.1.2.1 Genome-wide association study (GWAS)
The genome-wide association study(GWAS) focuses on finding the association
between the phenotype of interest and genetic variants across the genome.8 The
unit of genetic variation GWAS is called single nucleotide polymorphism or SNP,8
referring to one unit base-pair variation in a specific genomic location. The number
of detectable SNPs ranges from 1 million to 10 million depending on the depth of
3
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genotyping technology used. The genotyping technology has also evolved rapidly and
the cost of genotyping an individual has become much more affordable in recent years.
Large consortia have formed to provide power to scan millions of SNPs without
any prior hypothesis or knowledge. GWAS using large populations to find disease
related genetic variants took off in 2007. For example, the Wellcome Trust consor-
tium from UK conducted a GWAS study on 14,000 cases of seven diseases.9 With
a substantial number of GWAS published, methods on interpreting and prioritizing
GWAS results,10 and reflections on what GWAS can contribute to our knowledge
have resulted.11
In psychiatric disorders, several genome-wide association studies (GWAS) have
been carried out for five major psychiatric disorders,12 and have been most successful
in schizophrenia with 108 genetic loci and more to come.1
GWAS study on psychiatric disorders provide many biologically meaningful entry
points for further investigation. Many significant genetic variants across psychiatric
disorders have been shown to be enriched for SNPs that associate with expression
levels, particularly in brain.12,13 These functional genetic variants and related genes
provide insights on the underlying biological mechanism. In schizophrenia, a GWAS
informed strong genetic variant is found in the major histocompatibility complex
locus.14 The downstream biological studies showed that this variant in involved in
synapse elimination during brain development and sheds some insight on the biological




to environmental exposures.18 Thus,Epigenetics is an important area to the study
gene and environment interaction.
Epigenetics is defined as all heritable changes in gene expression that are not coded
in the DNA sequence itself, and DNA methylation is one of the most commonly mea-
sured epigenetic markers.19 A recent review paper on substance use disorder has
summarized several important CpG sites associated with substance use such as al-
cohol and tobacco use in animal and human studies.20 It was also shown that DNA
methylation patterns from 26 CpG sites at 3-5 years of age can accurately classify
prenatal exposure to smoking.21 There is also literature suggesting DNA methyla-
tion may play a role in Autism Spectrum Disorders(ASD) and other developmental
disorders.22,23
A goal of epigenetics research is the identification of markers that can serve as
either biomarkers for environmental exposure, or starting points for downstream eti-
ology research. Thus, just like GWAS, epigenome-wide association studies (EWAS)
can also shed light on psychiatric disease. By scanning possible associations between
phenotype and 450,000 to 850,000 DNA methylation markers across epigenome, bio-
logically interesting epigenetics markers may come to light.
6
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1.1.3 Injection Drug Use(IDU) and HIV
1.1.3.1 Epidemiology
There are estimated to be 11.0-21.2 million injection drug users (IDUs) world-
wide in 2007, with HIV prevalence over 40% among IDUs in nine countries.24 The
prevalence of substance use is high in the US, with prevalence of 13.8% in 2012-2014
in large metropolitan areas in a national survey of reported past-month use of any
illicit substance.25 According to the most recent results on National Survey of Drug
Use and Health, there were about 475,000 people aged 12 or older who were injecting
heroin in 2016 in the US.26 Estimates of cocaine use in 2016 were approximately 1.9
million people in the US.
Baltimore has had significant drug use problems for many years, and the AIDS
Linked to the Intravenous Experience (ALIVE) study recruited injection drug users
in Baltimore city and, to a small extent, surrounding counties.27 While a wealth of
studies has been conducted in the ALIVE Cohort, a particular study examining lon-
gitudinal injection drug use patterns is most relevant. In Figure 1.2, five distinct drug
use patterns over time were shown (early cessation, delayed cessation, late cessation,
frequent relapse and persistent injection).2 Heavy drug use was also shown to be a
barrier to HIV treatment initiation and adherence.28 Drug use remains a major issue
that undermines people’s health in Baltimore.




health are still unknown, and it is hard to develop a valid biomarker for recent (e.g.,
past six month) injection drug use. Genetics studies, especially epigenetics studies
open a door to better understand the changes in genomic and physiologic profiles
in response to injection drug use and HIV, and possibly as a biomarker for recent
injection drug use.
1.1.3.2 Genetics and Epigenetics
Evidence has shown that injection drug use is associated with biological modifi-
cation of the genome, i.e., epigenetics markers such as DNA methylation and histone
modification.38,39 For example, the human mu opioid receptor (OPRM1) gene is
shown to be associated with opioid injection use.40 Several studies have shown that
methylation near OPRM1 gene is associated with opioid use disorder, or changes
in methylation in animal models. However, these approach do not assess the entire
epigenome for associations.41,42
Up to now, the epigenome-wide association studies have been primarily conducted
in tobacco and alcohol use in humans.42 Thus, it is critical to study mechanisms of
how injection drug use affects human health by comprehensively examine the entire
epigenome.
In HIV, recent studies have shown that there are epigenetic signals associated
with HIV infection.43,44 The top CpG signal associated gene NLRC5 in these studies
have also presented in HIV integration sites.45 There is also other evidence that
9
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epigenetics may play a role in HIV latency.46 It will be interesting to further study
the epigenome with better coverage of CpG sites and with careful adjustment for cell
type heterogeneity between HIV positive and negative samples.
1.1.4 Autism Spectrum Disorder(ASD)
1.1.4.1 Epidemiology
Autism Spectrum Disorder (ASD) includes a range of complex neurodevelopmen-
tal disabilities characterized by social and communication impairments, as well as
restricted, repetitive, and stereotyped patterns of behavior according to DSM-5.47
ASD affects 1 in 68 children in the US according to estimates from CDC’s Autism
and Developmental Disabilities Monitoring Network.48 Studies in Asia, Europe, and
North America have identified children with ASD with median of prevalence estimates
of autism spectrum disorders of 62/10,000.49 Compared with non-ASD-associated ill-
nesses, ASD was associated with $3020 higher health care costs and $14.061 higher
non-health care costs.50 Most families reported high levels of burden following their
child’s diagnosis.51 The forecast annual direct medical, direct non-medical, and pro-
ductivity costs of ASD combined will be $461 billion (range $276-$1011 billion; 0.982-
3.600 % of GDP) for 2025.52 However, there is no medication that can cure Autism
Spectrum Disorders, but several behavior interventions during early development can
greatly improve autistic childrens social performance.53 In order to better understand
10
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the causes of ASD and develop effective medication, there is a great need for research
in ASD etiology.
1.1.4.2 Genetics and Epigenetics
The heritability of Autism Spectrum Disorder (ASD) is estimated to be about
50%, suggesting genetic factors play a major role in its etiology.54–56 Several genome-
wide association studies (GWAS) have been carried out for ASD in hopes of identi-
fying common genetic variants that are associated with risk.12,57–59 However, these
have thus far likely been underpowered, since most GWAS assess the whole genome
consisting of millions of single-nucleotide polymorphisms (SNPs), and few consistent
inherited common risk variants have been identified.
The identified common genetics variants, inherited and de novo rare variation,
copy number variants, contribute not specific to Autism, but related with other neu-
rodevelopmental disorders such as intellectual disability and fragile X syndrome.55,60,61
Epigenetics evidence also suggests possible shared biological mechanism among neu-
rodevelopmental disorders.23
Neurodevelopmental disorders are a group of conditions during the developmental
period characterized by developmental deficits that produce impairments of personal,
social, academic, or occupational functioning.47 According to CDC, about 1 in 6 chil-
dren in the United States had a developmental disability in 2006-2008.62 Intellectual
disability, one common type of neurodevelopmental disorders, often comorbid with
11
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ASD.63 Some neurodevelopmental disorders like fragile X syndrome, shared similar
symptoms and risk genetic variants with ASD.61
Significant genetic variants across psychiatric disorders thus far have been shown
to be enriched for SNPs that associate with expression levels, particularly in brain.12,13
These expression-associated SNPs are often termed expression quantitative trait loci
(eQTLs). Emerging studies on expression in the brain and brain eQTLs have been
recently published, and their data are publicly available.64,65 Hence, with existing
information on brain eQTLs applied, the testing space for GWAS is reduced to only
SNPs known to control brain expression levels, and thus efficiently increase the sta-
tistical power of GWAS and require smaller sample sizes.66,67 The approach can be
further limited to brain eQTLs that are associated in brain development or specific
brain region. Head circumference and imaging studies of toddlers with autism have
identified that deviant brain overgrowth majorly occurs during the first five years
of life in children with autism, and functional abnormalities are majorly found in
cortex.68,69 Subsetting SNPs to specific developmental period and/or brain regions
further reduce the testing space and may focus on more relevant and meaningful
genetic variants associated with ASD.
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1.2 Statement of Aims
1.2.1 Aim 1
Aim 1: Conduct epigenome-wide association analyses on injection drug use (any
current injection drug use, cocaine injection, heroin injection, etc.) in the ALIVE
cohort. Each substance will be assessed separately, and generalized estimating equa-
tions (GEE) will be used to accommodate the longitudinal study design. Apply the
statistical method correlation motif to jointly assess the epigenetic profiles of all types
of injection drug use in the ALIVE cohort.
1.2.2 Aim 2
Aim 2: Conduct the epigenome-wide association analyses on HIV infection status
and HIV viral load in the ALIVE cohort, and assess how injection drug use status
affects HIV epigenetic profiles.
1.2.3 Aim 3
Aim 3: Conduct genome-wide association analyses(GWAS) in Autism Spectrum
Disorder in the SEED study, and further subset the GWAS SNPs to brain eSNPs and
compare the shapes of QQ plots.
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1.3 Public Health Significance
The high HIV prevalence among IDUs is a substantial public health challenge
world-wide.34,70,71 IDUs often have faster HIV progression rate and worse HIV treat-
ment outcome compared with non-IDUs.33,34,71 However, few studies have examined
the underlying biological mechanisms by which injecting drugs like opioid affects hu-
man metabolism. To address the gaps in the literature, we propose a novel epigenome-
wide association analysis to investigate the DNA methylation changes due to drug
injection.
Epigenetics studies in humans is important because it enables discoveries. A large
amount of opioid studies take advantage of mice models and experiments that are
infeasible in humans due to constraints in tissue collection and ethical concerns.
Identifying the significant regions in the epigenome could lay a good foundation
for further discovery on the exact biological pathways of opioid and cocaine injection.
It is also worth noting that this study focuses on minority populations since the
majority of samples in the ALIVE cohort are African-Americans, which are commonly
underrepresented in genetic research. Evidence has shown that the racial disparity
among IDUs is striking, with higher HIV prevalence in blacks compared with whites.72
However, few genetic or epigenetic studies have focused on this population to inves-
tigate the etiology. Our study aims to fill in this gap and contribute to the overall
understanding of the etiology of drug addiction and HIV progression in humans.
Multiple studies have reported increased prevalence of ASD.73–75 Despite the in-
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creasing trend of diagnosis of ASD, the etiology of ASD remains unknown and no
medication has been developed to fully cure ASD. Genes have long been known to
play a major role in ASD and are believed to provide important information on the
underlying biological mechanism of ASD. However, due to lack of statistical power to
test across the whole genome, few significant genetic variants were discovered and no
consistent variants were found. Given the challenges of identifying common genetic
variants associated with ASD in only moderately sized samples, strategic subsetting
of the genome into relevant regions likely to harbor risk is a rational approach to
a practical problem. Identification of significant brain eQTL SNPs associated with
ASD can shed immediate light on the potential functionality of the association and
therefore improve understanding of ASD mechanisms, which may further improve our





2.1.1 The AIDS Linked to the IntraVenous Expe-
rience (ALIVE) Study
The ALIVE study is a prospective cohort study characterizing the incidence and
natural history of HIV infection among injection drug users (IDUs) in Baltimore,
MD.27 DNA methylation were collected by Illumina Methylation EPIC bead chip
and in January 2016 for about 800 individuals.
At study inception, HIV serologic screening of 2,960 IDUs identified a cohort of
668 seropositives followed biannually with interviews, exams and biospecimen col-
lection.27 In parallel, HIV seronegative subjects were followed through ALIVE-1
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(as immunological controls, N 150) and the ALIVE-2 cohort (N 1000). Through
ALIVE-2 screening, 328 HIV seroconverters have been identified and followed in the
HIV-positive protocol. Additional recruitment in 1994-95, 1998, 2000 and 2005-08
replenished a total of 454 HIV-infected and 1208 uninfected IDUs. Follow-up expe-
rience by recruitment period indicates that 4% die and 7% are lost to follow-up
annually.
At each 6-month study visit, participants undergo 1) standardized questionnaires
(interviewer- and computer-administered); 2) a locator form to record participant
address and contacts; 3) clinical exam, and 4) biological specimen collection for rou-
tine laboratory and repository. Records from all reported medical encounters are
requested with standardized abstraction for clinical outcomes. Linkage to adminis-
trative, disease and mortality databases provide additional endpoints.
ALIVE remains predominantly African American and majority male with a me-
dian age exceeding 50 years. From 90% actively injecting at study entry, less than
one-third of current HIV-infected participants are active injectors. Non-injection drug
use (mainly crack), smoking (79%) and regular alcohol use (43%) are highly prevalent.
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2.1.2 The Study to Explore Early Development
(SEED) Study
The SEED study consists of 1309 samples, with 584 Autism Spectrum Disorder
(ASD) cases and 725 normal controls with multiple ancestry, and over 30 million
single-nucleotide polymorphisms (SNPs) that passed quality control (QC). The geno-
typing platform used was either the Illumina Omni1M Quad or the Affymetrix Kaiser
Axiom array. The QC measures included removal of samples with low call rates
(<98%), sex discrepancies, inappropriate relatedness (pi-hat > 0.2), and/or excess
heterozygosity or homozygosity, removal of SNPs with a minor allele frequency less
than (MAF<5%), and flagging of SNPs statistically significant (p < 10−6) for not be-
ing in Hardy Weinberg Equilibrium in ancestry-stratified control samples. Following
application of QC filters, phasing was performed using SHAPEIT followed by impu-
tation against the 1000 Genome Project panel using IMPUTE2, resulting in over 30
million SNPs per sample. Ten principal components representing the multiple genetic
ancestry of each sample were used to adjust for ancestry in GWAS analyses.
2.1.3 Psychiatric Genomics Consortium (PGC)
The Psychiatric GWAS consortium76 aims to integrate genomic data on psychi-
atric disorders from different sources to conduct GWAS meta- and mega-analyses.
The consortium greatly increases the power of GWAS analysis and has contributed
18
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preliminary findings on the genetic and biological basis of psychiatric disorders like
schizophrenia. The pioneer publication12 on five psychiatric disorders including autism
sparked further genomics and functional genomics analyses on psychiatric disorders.
The PGC-AUT panel was reported to have 3,303 cases and 3,428 controls. The
most recent PGC-AUT has 9 million imputed SNPs available for analysis. However,
only summary data such as SNP reference ID, effect size and p-value is available to
download; we currently do not have access to raw data.
2.2 Longitudinal analysis
Many longitudinal studies quantified epigenetics patterns over time.77 To examine
the change in epigenetics profiles across time, we need to account for repeated mea-
surements on the same subjects in the longitudinal design. Researchers have previ-
ously reported longitudinal changes in candidate epigenetics sites78 using mixed effect
model with random intercept. Other statistical methods that account for longitudinal
design includes generalized estimating equations(GEE) and variance components.79
When these longitudinal methods applied into epigenome-wide analyses, com-
putational time to account for longitudinal design is much longer than candidate
epigenetics sites approaches. The following sections described two methods that can
perform epigenome-wide longitudinal analyses within hours.
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2.2.1 Linear mixed effect model
A linear mixed effect model handles correlation on the dependent variable by
introducing random effect components.80 In a mixed effect model, fixed effect pa-
rameters measure population mean response(between subject variation) just like the
conventional linear model, and the random effect parameters model the variability of
response from the same individual(within subject variation). By specifying a random
intercept in the mixed model, the baseline level of response is considered random and
subject-specific, and in this way it handles the innate correlation within subject.
Mixed effect modeling is a popular method in longitudinal cohorts, but when
applied to genome-wide studies, the traditional R package lme4 takes about 1 hour
to compute 10 CpG sites.81 Several mixed effect model packages in GWAS have been
developed to account for population structure.82–85 However, the only R package that
can transfer to epigenetics data is the lrgpr R package with specification of the genetic
similarity matrix K to be the block identity matrix based on subject ID.82 The results
based on linear mixed models were generated using the lrgpr package.
2.2.2 Generalized Estimating Equations (GEE)
The Generalized Estimating Equation (GEE) is another statistical method that
can account for a longitudinal design.86 However, instead of modeling the covariance







transformed version of beta value, referred to as the M value ranging from −∞ to ∞.
β =
Methylated intensity
Methylated intensity + Unmethylated intensity + 100
M = log2
Methylated intensity + 1
Unmethylated intensity + 1
Beta values are often easier to interpret in terms of biological meaning, whereas
the M value distribution is more normal and less variable.93 Some researchers have
argued that the M value is preferred in epigenetics analysis with better a detection
rate and true positive rate.93 The intensity of raw beta values by two Illumina probe
types are shown in Figure 2.4.
2.3.1.3 Probe filter
In addition to low intensity probes, probe filters on detection p-value, cross re-
active probes and probes that are single nucleotide polymorphisms (SNPs) are com-
monly used.
Detection p-value quantifies the probability of detecting the intensity from the
background noise, not from the true signal.90 Probes that have p > 0.05 are considered
not likely to be the true signal and usually filtered out. The distribution of failed
fraction of sample per probe by detection p-value is shown in Figure 2.5.
Some probes in the Illumina array are mapped to multiple parts of the genome,







The SVA and ISVA methods can account for unknown batch effects,99,100 but when
implemented in our data, it generates more than 200 SVs and cannot be applied di-
rectly to longitudinal methylation data. The RUV method utilized negative control
features that are only correlated with technical variations.101 We can extract top PCs
from those negative control probes and it can be directly applied to longitudinal data.
Figure 2.8 shows the top negative control PCs that capture batch effect by plate.
2.3.2 Cell composition estimation
DNA methylation is greatly affected by cell type, and thus adjusting for cell
composition is very important in DNA methylation related analyses.103 The cell
composition can be estimated either by reference-based methods or reference free
methods.96,104 The widely used reference based method is obtained by 46 blood
samples from people of European ancestry,96 and thus may not be as accurate when
applying to samples of different ancestry or with infection such as HIV. The reference
free approach gives flexibility to accommodate different sources of data, but the users
need to specify number of clusters and the estimated variables are hard to interpret.104
We obtained measured CD4+ and CD8+ cell proportions from about 200 blood
samples and compare them with the estimated Houseman cell proportions in Figure








2.4 Joint analysis by correlation motif
In any genetics and epigenetics studies, usually multiple phenotypic measures
were collected for the sample. These phenotypes are usually correlated, for example,
different types of drug use status for the past six months. Typically, we run separate
genetics and epigenetics analyses on these phenotypes, ignoring the fact that there
are potential correlation between the analyses. A joint analysis over these correlated
phenotypes can be a better approach. By borrowing information across phenotypes,
we may detect genetic or epigenetic variants that cannot be discovered by separate
analyses alone. By using the summary level statistics, we want to examine if there
are groups of genetic or epigenetic variants with the same patterns of association
across the phenotypes. By accounting for the correlation across phenotypes, we can
generate new statistics that may lead to new discovery and insight to the phenotype
of interest.
There are existing methods in GWAS for jointly analyzing different phenotypes to
detect significant SNPs. The method ASSET search through subsets of phenotypes
to find the optimal subset for meta-analysis.112 MultiPhen tests the association be-
tween SNP and the linear combination of phenotypes.113 However, not many of these




bg with probability π = (π1, ..., πK), where πk = Pr(bg = k) and
∑
k πk = 1. The
probability of any gene in class bg = k to be associated with study d is defined as
qkd = Pr(agd = 1|bg = k), which is the correlation structure between groups of genes
and study. f0 is the null distribution of tgd and f1 is the alternative distribution.
This method extracts correlation structure πk, qkd referred as a correlation motif,
and then calculates the posterior probability based on the correlation motif as a prior





























where we use a Dirichlet prior for π and a beta prior B(2, 2) for qkd.
To determine the optimal number of group K, we use Bayesian information cri-
terion(BIC) as the indicator for model selection. The output is whether each gene
g is significant in study d, i.e., agd, and is by default determined by the posterior
probability greater than 0.5.
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2.4.2 Correlation motif applied in DNA methyla-
tion data
To make the correlation motif method applicable to different phenotypes in DNA
methylation data, we made several changes to the model. First, we used p-values
instead of test statistics as summary statistic input from separate analyses. Second,
the null distribution f0 is assumed to be uniform (0,1), and the alternative distribution
f1 follows a beta distribution estimated by permutation. Third, we calculate the
local FDR using 1-posterior probability to ensure we can make comparisons between
separate analyses and joint analyses. Details on how to formulate the model and run
the EM algorithm are shown in the following sections.
2.4.2.1 E-step




































































[ln qkd + ln(1− qkd)] + constant
Thus, the expectation of loglikehood with respect to A,B|T, π̂oldQ̂old is:














































To obtain the maximum values after the E-step, we take the first order of partial




















g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k) + 2
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Details on how to derive the maximum is shown below:
To obtain π̂newk , since
∑K














































g=1 Prold(bg = k) + 1
]
∑G
g=1 Prold(bg = K) + 1
Since
∑K
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g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k, agd = 1) +
∑G
g=1 Prold(bg = k, agd = 0) + 2
=
∑G
g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k) + 2
By definition of Prold(bg = k), it is the total probability of genes assigned to motif k.
Thus,

















ld fd1(tgd) + (1− q̂
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kd fd1(tgd) + (1− q̂
(old)
kd )fd0(tgd)
∗ Prold(bg = k)
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The posterior distribution is given by:
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+(K − 1 +K ∗D) ∗ lnG
For missing data in phenotype d and CpG g, we have fd1(tgd) = 1 and fd0(tgd) = 1.
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In Prold(bg = k, agd = 1):






kd fd1(tgd) + (1− q̂
(old)
kd )fd0(tgd)
∗ Prold(bg = k)
= q̂kd ∗ Prold(bg = k)
Thus, we can substitute fd0(tgd), fd1(tgd) with 1 for the missing observations, and it
does not affect the final estimation. We also use the following formula to make sure
a and b are close to zero, the estimation process will remain accurate.


















elog a−logmax + elog b−logmax
)
2.4.2.3 Implementation of E-M algorithm










(1) a1,kdg = ln[q̂
(old)
kd fd1(tgd)]; for missing data, a1,kdg = ln q̂
(old)
kd (3d-array)
a2,kdg = ln[(1− q̂
(old)
kd )fd0(tgd)]; for missing data, a2,kdg = ln(1− q̂
(old)
kd ) (3d-array)
































d=1[ln(e1,kdg + e2,kdg) + amax,kdg] (2d-array)
logpmaxkg = pmax(logpkg) (2d-array)





(probability of a specific g belongs to motif
k, output, 2d-array)
(5) Prold(bg = k, agd = 1) =
e1,kdg
e1,kd + e2,kdg
∗ Prold(bg = k); (3d-array)
Prold(bg = k, agd = 0) =
e2,kdg
e1,kd + e2,kdg
∗ Prold(bg = k); (3d-array)
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g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k) + 2
(2d-array)
4. Repeat 2-3 for a maximum of n times, or when none of the parameters in π and
Q changes by more than 0.1%.





∗ Prold(bg = k)
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[ln qkd + ln(1− qkd)]





lnPr(T|π,Q) + (K − 1 +K ∗D) ∗ lnG
2.4.2.4 EM algorithm for estimating f0, f1
Set up:
1. Observed empirical p-values from permutation X.
2. Missing probability of belonging to null distribution for each CpG site Z.
3. Parameters to be estimated as listed below:
f = π0f0 + π1f1
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(1) f is the overall distribution.
(2) π0 is the probability of being in the null distribution (expected to be > 0.99);
needs to be estimated.
(3) π1 is the probability of being in the alternative distribution (expected to be
< 0.01); needs to be estimated.
(4) f0 is the null distribution with Unif(0,1)
(5) f1 is the alternative distribution with Beta(α,β) ; α, β needs to be estimated.
Steps:
1. Choose initial values for π0, π1, α, β.
π
(0)
0 = 0.99, π
(0)
1 = 0.01, α
(0) = 1, β(0)=30
2. Compute f based on initial values.
3. Compute posterior probability for each CpG site belonging to f0 as Z.







0 f0(pi) + π
(0)
1 f1(pi)






































5. Repeat 3-4 until converge.
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Epigenetics and Injection Drug Use
3.1 Introduction
There are estimated to be 11.0-21.2 million injection drug users (IDUs) world-wide
(estimate from 2007), with HIV prevalence over 40% among IDUs in nine countries.24
The prevalence of substance use is high in the US, with prevalence of 13.8% in 2012-
2014 in large metropolitan areas in national survey reported past-month use of any
illicit substance use.25 According to the most recent results on National Survey of
Drug Use and Health, there are about 475,000 people aged 12 or older were injecting
heroin in 2016 in the US.26 Estimates of cocaine use in 2016 were 1.9 million people
in the US.
The exact biological mechanisms of the impact of injection drug use on human
health are still unknown, and it is has been challenging to develop a valid biomarker
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for recent injection drug use given the difficulties in accessing subjects and samples.
Genetics studies, especially epigenetics studies open a door to better understand the
changes in epigenetic profiles in response to injection drug use, and possibly as a
biomarker for recent injection drug use.
Injection drug use is associated with substantial mortality and morbidity.29,30 In
Rome, the mortality risk among drug users was about 15 times higher compared to
population controls among men, and 38 times higher among women.29 Among in-
jection drug users in Baltimore, the estimated standardized mortality ratio remained
elevated excluding HIV-related mortality.31 Also, studies have shown that injection
drug users have much higher risk of HIV infection32 and worse HIV outcomes during
treatment initiation compared with non-IDUs. Notably, injection drug use may affect
HIV progression,33,34 and may lead to shortened disease-free survival time in HAART
treatment.34 Among frequently injected drugs, heroin is known to have immunosup-
pressive effects in human by affecting T lymphocyte functions and inhibiting T cell
signaling.35–37 Thus, it is important to examine how injection drug use impacts HIV
latency and progression.
3.2 Method
The ALIVE study is an on-going prospective cohort study characterizing the in-
cidence and natural history of HIV infection among injection drug users (IDUs) in
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Baltimore, MD from 1988.27 At each 6-month visit, clinical, behavioral and labora-
tory data such as HIV infection status and injection drug use were assessed for the
participants. Blood was obtained from 288 current IDUs, resampled after cessation
and then again after relapse (total samples = 774). HIV status did not change across
visits.
The study participants went through HIV serology screening at baseline. HIV
serology status was assessed at each study visit for HIV negative participants, whereas
CD4+, CD8+ count and HIV viral load testing were performed at each study visit
for HIV positive participants. Past six months injection drug use status and type,
smoking patterns, and ART use information were obtained by computer-administered
standardized questionnaires. The study design has been described in other litera-
ture.27,115,116
3.2.1 DNA methylation measurement and prepro-
cessing
Peripheral blood mononuclear cell DNA was isolated with the Qiagen DNeasy kit
and bisulfite converted with Zymo EZ methylation gold kit at the Johns Hopkins
University Center for Inherited Disease Research. Bisulfite treated DNA was run on
the Illumina Infinium MethylationEPIC BeadChip.
The minfi package (Bioconductor) was used to process raw Illumina image files
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into noob preprocessed methylation beta values.91 Cell composition on CD4+, CD8+,
natural killer cells, monocytes, granulocytes and B cells were estimated based on the
method described in Houseman et al.96 and implemented in minfi .91,103 Samples with
low intensity, inconsistency on predicted and observed sex, and outliers in estimated
cell composition were removed for quality control. Probes with low intensity or that
are known to cross-hybridize were excluded. 774 samples and 822,210 probes were
used in the final analyses. Batch effect was adjusted by top 4 PCs from negative
control features that are only correlated with technical variations.101 The pipeline of
proprecessing is in supplementary figure 3.5.
3.2.2 Statistical analysis
3.2.2.1 Separate analyses using linear mixed effect model
M value is used in the analysis since the M-value distribution is closer to normal
assumption and less variable. Researchers reported that the use of M value usually
leads to better detection rates and true positive rates compared with the beta value.93
We used a linear mixed effect model with random intercept to account for the
longitudinal design by using the R package lrgpr .82 The package is designed for fast
computation of mixed effect models to account for population stratification based
on GWAS data,82 but it allows flexibility on input data and the ability to manually
specify the variance-covariance matrix. Thus, we can directly use this package to run
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a linear mixed effect model with random intercept on epigenome-wide association












1, if i, j are from the same subject
0, otherwise
where K is a n× n matrix and n is the total sample size.
We conducted single site association analyses on heroin only, cocaine only and
heroin and cocaine co-use across the epigenome for the 822,210 CpG sites, adjusting
for HIV status, gender, race, age, smoking status, cell composition and PCs for batch
effect. The model is stated below(i indicates subject ID and t indicate time points):
Mit = ui + β0 + β1heroin onlyit + β2cocaine onlyit + β3co-useit + β4HIVit + β5genderit
+β6raceit + β7ageit + β8smokingit + β9CD4it + β10CD8it
+β11natural killer cellsit + β12monocytesit + β13granulocytesit + β14B cellsit
+β15negative control PC1it + β16negative control PC2it +
β17negative control PC3it + β18negative control PC4it
For the analysis of any injection drug use, we replaced heroin only, cocaine only
and co-use indicators with the overall indicator of any injection drug use. There are
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108 visits that are missing specific injected drug type, and we imputed the drug type
based on individual’s past injection drug types and age.
Mit = uit + β0 + β1injection drug useit + β2HIVit + β3genderit
+β4raceit + β5ageit + β6smokingit + β7CD4it + β8CD8it
+β9natural killer cellsit + β10monocytesit + β11granulocytesit + β12B cellsit
+β13negative control PC1it + β14negative control PC2it +
β15negative control PC3it + β16negative control PC4it
3.2.2.2 Joint analysis
After running separate epigenome-wide association analyses on any injection drug
use, heroin only, cocaine only and co-use, we extracted the p-values from 4 analyses for
each CpG sites and conduct joint analysis by correlation motif.114 We estimated the
correlation structure between groups of CpG sites and four phenotypes (any injection
drug use, heroin only, cocaine only and co-use) by E-M algorithm, and calculated
the posterior probability and local FDR incorporating the correlation structure. The
number of CpG group is determined by the model with lowest bayesian information
criterion(BIC). Details on the correlation motif method and its implementation in
epigenome-wide association analyses can be found in supplementary methods and
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Wei et al. 2014.114 We also acknowledge that the original method is developed under
conditional independence assumption, and any injection drug use is the sum of heroin
only, cocaine only and co-use of heroin and cocaine. Thus, the results from the model
should be interpreted carefully.
3.2.2.3 Gene ontology
The gene ontology enrichment analysis is done using in GO(Gene Ontology)




The sample characteristics are shown in Table 3.1. Among 288 subjects, about 2-4
visits per subjects were selected for methylation measurement illustrated in Figure
3.1. About half of visits were injection drug use visits for the past 6 months, and
the other half the subjects did not inject any drugs. About 2/3 of the visits were
male, and 1/3 of the visits were HIV positive. 92% of the samples were from African
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3.4 Discussion
There is a general lack of knowledge on how injection drug use affects DNA methy-
lation in humans. Evidence on the effect of heroin and cocaine use in human and mice
models has focused on either methylation on specific genes like OPRM1, or global
methylation or demethylation.117,118 The development of methylation profiling mi-
croarray technology allowed us to measure millions of CpG sites at lower cost and
conduct epigenome-wide association studies(EWAS). EWAS in smoking and alcohol
have revealed the utility of epigenetic sites as biomarker for smoking, maternal smok-
ing and alcohol consumption.21,119–121 It is highly possible that there exists epigenetic
markers associated with injection drug use such as heroin and cocaine.
The separate joint analyses provided several CpG sites and genomic region of
interest, and can be further explored by biological studies. Joint analyses also revealed
groups of CpG sites that contribute to any injection drug use. However, compared
to a recent EWAS analysis, there is no overlap between the identified CpG sites and
genes.122 Since the authors made comparison between lifetime injection drug use (and
HCV+) vs. none injection drug use (and HCV-) among HIV infected people, which is
different from our phenotype of interest, there might be underlying difference on the
overall human conditions. With more data on DNA methylation on humans, meta-
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expressed in study d. The proposed method first finds K groups of genes that have
similar differential expression pattern across different studies with the group label as
bg with probability π = (π1, ..., πK), where πk = Pr(bg = k) and
∑
k πk = 1. The
probability of any gene in class bg = k to be associated with study d is defined as
qkd = Pr(agd = 1|bg = k), which is the correlation structure between groups of genes
and study. f0 is the null distribution of tgd and f1 is the alternative distribution.
This method extracts correlation structure πk, qkd referred as correlation motif,
and then calculates the posterior probability based on the correlation motif as prior





























where we use a Dirichlet prior for π and a beta prior B(2, 2) for qkd.
To determine what is the optimal number of groupK, we use bayesian information
criterion(BIC) as the criterion. The output is whether each gene g being significant
in study d, i.e., agd, and is by default determined by the posterior probability greater
than 0.5.
Correlation motif applied in DNA methylation data
To make correlation motif method applicable to different phenotypes in DNA
methylation data, we make several changes to the model. First, we used p-values
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instead of test statistics as summary statistic input from separate analyses. Second,
the null distribution f0 is assumed to be uniform (0,1), and the alternative distribution
f1 follows a beta distribution estimated by permutation. Third, we calculate the
local FDR using 1-posterior probability to ensure we can make comparison between
separate analyses and joint analyses. Details on how to formulate the model and run
the EM algorithm is shown in the following sections.
3.5.2.1 E-step


































































[ln qkd + ln(1− qkd)] + constant
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Thus, the expectation of loglikehood with respect to A,B|T, π̂oldQ̂old is:










































[ln qkd + ln(1− qkd)] + constant
3.5.2.2 M-step
To obtain the maximum values after the E-step, we take the first order of partial






















g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k) + 2
Details on how to derive the maximum is shown below:
To obtain π̂newk , since
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g=1 Prold(bg = k) + 1
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∑G
g=1 Prold(bg = K) + 1
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Since
∑K









g=1 Prold(bg = k) + 1
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g=1 Prold(bg = k) + 1
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g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k, agd = 1) +
∑G
g=1 Prold(bg = k, agd = 0) + 2
=
∑G
g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k) + 2
By definition of Prold(bg = k), it is the total probability of genes assigned to motif k.
Thus,
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kd fd1(tgd) + (1− q̂
(old)
kd )fd0(tgd)
∗ Prold(bg = k)
The posterior distribution is given by:
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+(K − 1 +K ∗D) ∗ lnG
For missing data in phenotype d and CpG g, we have fd1(tgd) = 1 and fd0(tgd) = 1.





kd fd1(tgd) + (1− q̂
(old)




kd + (1− q̂
(old)
kd )] = π̂
(old)
k
In Prold(bg = k, agd = 1):






kd fd1(tgd) + (1− q̂
(old)
kd )fd0(tgd)
∗ Prold(bg = k)
= q̂kd ∗ Prold(bg = k)
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Thus, we can substitute fd0(tgd), fd1(tgd) with 1 for the missing observations, and it
does not affect the final estimation. We also use the following formula to make sure
a and b are close to zero, the estimation process will remain accurate.


















elog a−logmax + elog b−logmax
)
3.5.2.3 Implementation of E-M algorithm










(1) a1,kdg = ln[q̂
(old)
kd fd1(tgd)]; for missing data, a1,kdg = ln q̂
(old)
kd (3d-array)
a2,kdg = ln[(1− q̂
(old)
kd )fd0(tgd)]; for missing data, a2,kdg = ln(1− q̂
(old)
kd ) (3d-array)






























d=1[ln(e1,kdg + e2,kdg) + amax,kdg] (2d-array)
logpmaxkg = pmax(logpkg) (2d-array)
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(probability of a specific g belongs to motif
k, output, 2d-array)
(5) Prold(bg = k, agd = 1) =
e1,kdg
e1,kd + e2,kdg
∗ Prold(bg = k); (3d-array)
Prold(bg = k, agd = 0) =
e2,kdg
e1,kd + e2,kdg
∗ Prold(bg = k); (3d-array)
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g=1 Prold(bg = k, agd = 1) + 1
∑G
g=1 Prold(bg = k) + 2
(2d-array)
4. Repeat 2-3 for a maximum of n times, or when none of the parameters in π and
Q changes by more than 0.1%.





∗ Prold(bg = k)
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lnPr(T|π,Q) + (K − 1 +K ∗D) ∗ lnG
3.5.2.4 EM algorithm for estimating f0, f1
Set up:
1. Observed empirical p-values from permutation X.
2. Missing probability of belonging to null distribution for each CpG site Z.
3. Parameters to be estimated as listed below:
f = π0f0 + π1f1
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(1) f is the overall distribution.
(2) π0 is the probability of being in the null distribution (expected to be > 0.99);
needs to be estimated.
(3) π1 is the probability of being in the alternative distribution (expected to be
< 0.01); needs to be estimated.
(4) f0 is the null distribution with Unif(0,1)
(5) f1 is the alternative distribution with Beta(α,β) ; α, β needs to be estimated.
Steps:
1. Choose initial values for π0, π1, α, β.
π
(0)
0 = 0.99, π
(0)
1 = 0.01, α
(0) = 1, β(0)=30
2. Compute f based on initial values.
3. Compute posterior probability for each CpG site belonging to f0 as Z.







0 f0(pi) + π
(0)
1 f1(pi)


































i wi(pi − µ̂)
2
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The incidence of HIV has declined between 2011 and 2015.123 With appropriate
antiretroviral treatment and care, the life expectancy of HIV-infected patients even
approaches uninfected individuals.124 HIV has become a chronic disease, but latent
HIV induces chronic inflammation and has led to HIV many related commorbidity and
complications such as cardiovascular disease and dementia.125 Chronic HIV infection
has a long-term impact on the immune system, but the exact biological mechanisms
affected are not known.
Epigenetics studies open a door to better understanding the changes in epigenetic
profiles with chronic HIV infection. Acute HIV infection on CD4+ and CD8+ cell
lines is proved to be associated with global methylation changes in vitro.126 There is
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also evidence that HIV latency is regulated by DNA methylation and histone mod-
ification.46,127,128 DNA methylation level in viral promoter such as the HIV long
terminal repeat(LTR) region affect viral gene expression.128 Thus, epigenetic analy-
ses may provide potential drug targets to remove latent virus reservoir.129
Recent studies have shown that there are epigenetic signals associated with HIV
infection in the NLRC5 and HLA genes.43,44,130 The top CpG signal associated
gene region in these studies has also presented in HIV integration sites.45 It will
be interesting to further study the epigenetics signal with better coverage of CpG
sites and with careful adjustment for cell type heterogeneity between HIV positive
and negative samples.
Studies have shown that injection drug users have much higher risk of HIV infec-
tion32 and worse HIV outcome during treatment initiation compared with non-IDUs.
Notably, injection drug use may affect HIV progression,33,34 and may lead to short-
ened disease-free survival time in HAART treatment.34 Injection drug users were
shown to be less likely to engage in HIV care.131 Among frequently injected drugs,
heroin is known to have immunosuppressive effects in human by affecting T lympho-
cyte functions and inhibiting T cell signaling.35–37 It would be also interesting to
examine how injection drug use affects HIV latency.
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4.2 Method
4.2.1 Study samples
The ALIVE study is an on-going prospective cohort study characterizing the in-
cidence and natural history of HIV infection among injection drug users (IDUs) in
Baltimore, MD from 1988.27 At each 6-month visit, clinical, behavioral and labora-
tory data such as HIV infection status and injection drug use were assessed for the
participants. Blood was obtained from 288 current IDUs, resampled after cessation
and then again after relapse (total samples = 774). HIV status did not change across
visits.
In order to avoid repeated measurement on the same subjects with the same HIV
status and confounding by injection drug use, we randomly select one visit without
any past six month injection drug use, and the total sample size is 281 subjects with
182 HIV positives, 99 HIV negatives. For sensitivity analyses, we also randomly
select one visit with any past six month injection drug use, and the sample size is 218
subjects with 147 HIV positives, 71 HIV negatives.
The study participants went through HIV serology screening at baseline. HIV
serology status was assessed at each study visit for HIV negative participants, whereas
CD4+, CD8+ count and HIV viral load testing were performed at each study visit for
HIV positive participants. Past six injection drug use status and type, smoking pat-
terns, and ART use information were obtained by computer-administered standard-
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ized questionnaires. The study design had been described in other literature.27,115,116
4.2.2 DNA methylation measurement and prepro-
cessing
Peripheral blood mononuclear cell DNA was isolated with the Qiagen DNeasy kit
and bisulfite converted with Zymo EZ methylation gold kit at the Johns Hopkins
University Center for Inherited Disease Research. Bisulfite treated DNA was run on
the Illumina Infinium MethylationEPIC BeadChip.
The minfi package (Bioconductor) was used to process raw Illumina image files
into noob preprocessed methylation beta values.91 Cell composition on CD4+, CD8+,
natural killer cells, monocytes, granulocytes and B cells were estimated based on the
method described in Houseman et al.96 and implemented in minfi .91,103 Samples with
low intensity, inconsistency on predicted and observed sex, and outliers in estimated
cell composition were removed for quality control. Probes with low intensity or that
are known to cross-hybridize were excluded. 774 samples and 822,210 probes were
used in the final analyses. Batch effect was adjusted by top 4 PCs from negative
control features that are only correlated with technical variations.101 The pipeline of
proprecessing is in supplementary figure 4.7.
Since HIV infection is known to be associated with lower CD4+ count and higher
CD8+ count, in addition to the estimated cell composition, we also adjusted for top
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6 PCs of 1,000 most significant CpGs that are positively associated with CD8+ but
negatively associated with CD4+ by using the R package FlowSorted.Blood.450k on
Illumina HumanMethylation data on sorted blood cell populations.132
4.2.3 Statistical analysis
M value is used in the analysis since the M-value distribution is closer to the
assumption of normality and less variable. Researchers reported that the use of M
value usually leads to better detection rates and true positive rates compared with
the beta value.93
We used limma to run single site association analyses with HIV infection status
across the epigenome for the 822,210 CpG sites, adjusting for gender, race, age, smok-
ing status, cell composition, PCs for batch effect, and additional 6PCs representing
more CD8+ and less CD4+. The model is stated below:
Mi = β0 + β1HIVi + β2genderi + β3racei + β4agei + β5smokingi + β6CD4i + β7CD8i
+β8natural killer cellsi + β9monocytesi + β10granulocytesi + β11B cellsi
+β12negative control PC1i + β13negative control PC2i +
β14negative control PC3i + β15negative control PC4i
+β16CD8/CD4 PC1i + β17CD8/CD4 PC2i + β18CD8/CD4 PC3i
+β19CD8/CD4 PC4i + β20CD8/CD4 PC5i + β21CD8/CD4 PC6i
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For sensitivity analyses among 218 injection drug use visits, we additionally used
type of injection drug use (heroin only injection, cocaine only injection and other) as
covariates.
The gene ontology enrichment analysis is done using in GO(Gene Ontology)
database106 by the R pacakage missMethyl, with prior to correction for sampling
bias.108,109 We used the epigenetic clock to estimate the biological age by the method
described in Horvath et al.110
4.3 Results
4.3.1 Cell composition
There were significant differences on CD4+ cell proportion and CD8+ cell propor-
tions by HIV status (Figure 4.1). HIV infected majorly on CD4+ cells, and induced
decrease in CD4+ cells and increase in CD8+ cells. These changes were reflected in
estimated cell proportions in Figure 4.1.
We obtained measured CD4+ and CD8+ count and proportions for 230 HIV+ vis-
its and 39 HIV- visits, and made comparison between estimated CD4+/CD8+ ratio
vs. measured CD4+/CD8+ ratio in Figure 4.2. The estimated CD4+/CD8+ ratio is
similar to the measured ratio, but there are many outliers and there is significant dif-
ference by HIV between estimated and measured CD4+/CD8+ ratio (p=0.047). This
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chronic HIV infection patients.45 This change in DNA methylation may be a result
of either chronic infection by HIV virus, or HIV integration near this gene. Further
biological experiments on this gene can shed light on how chronic HIV infection affects
the immune system.
It is also interesting to explore how injection drug use modify chronic HIV in-
fection’s effect on the immune system. There is about 30% concordance between
the non-injection visits and injection visits, indicating interaction effect of injection
drug use and chronic HIV infection on DNA methylation in blood cells. Integrat-
ing injection drug use methylation markers in chronic HIV infection research may be
interesting.









Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized
by significant social impairment and repetitive behaviour.47 ASD is highly heritable,
suggesting genetic factors play a major role in its etiology.54 However, there is limited
success in genome-wide association study (GWAS) on ASD due to small sample size.12
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Many studies on psychiatric genetics, including ASD, studies have shown that many
of the genes implicated in polygenic risk are involved in regulating gene expression
and translation in the brain. These genetic variants are known as Brain expression
quantitative trait loci, or Brain eQTLs. In the context of GWAS, we specifically refer
to SNPs that are brain eQTLs as Brain eSNPs. These Brain eSNPs may pinpoint
functionally important findings in GWAS and elucidate biological pathways associated
with ASD.67 Recent literature has shown that brain-informed eQTL annotation of
genetic variants can enable us to discover novel variants in ASD.133 However, due to
limited sample sizes, studies on ASD GWAS often fail to report significant genetic
variants. One approach to reducing the burden of multiple testing is to subset the
scope of candidate SNPs in a GWAS panel to brain eSNPs. This in turn may help us
detect functionally relevant SNPs. Further subsetting brain eSNPs to those specific
to brain region may help us pinpoint brain regions of interest in ASD etiology. To our
knowledge, no one has yet performed an ASD GWAS using candidate brain eSNPs
informed by brain eQTL studies. We propose a brain eSNPs informed analysis on
our GWAS sample, the Study to Explore Early Development.
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5.2 Method
5.2.1 Overview
We describe the GWAS samples we are going to use, how we obtained brain
eQTLs from existing literature, and how we created pruned all SNPs, brain eSNPs
and brain region specific eSNPs subsets. Genome-wide association study (GWAS)
Sample The Study to Explore Early Development (SEED). The SEED study consists
of 1,309 samples, with 584 Autism Spectrum Disorder (ASD) cases and 725 normal
controls with multiple ancestry, and over 30 million single-nucleotide polymorphisms
(SNPs) that passed quality control (QC). The genotyping platform used was either
the Illumina Omni1M Quad or the Affymetrix Kaiser Axiom array. The QC measures
included removal of samples with low call rates (< 98%), sex discrepancies, inappro-
priate relatedness (π̂ > 0.2), and/or excess heterozygosity or homozygosity, removal
of SNPs with a minor allele frequency less than (MAF< 5%), and flagging of SNPs
statistically significant (p < 10−6) for not being in Hardy Weinberg Equilibrium in
ancestry-stratified control samples. Following application of QC filters, phasing was
performed using SHAPEIT followed by imputation against the 1000 Genome Project
panel using IMPUTE2, resulting in over 30 million SNPs per sample. Ten principal
components representing the multiple genetic ancestry of each sample were used to
adjust for ancestry in GWAS analyses.
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5.2.2 Brain eSNP Data Sets
Brain eSNPs were extracted from 6 published brain eQTLs studies, and the brain
tissues were from neurologically normal individuals and those with psychiatric disor-
ders in Supplementary Table 5.2,65,134–138 with annotation for 11 different brain tissue
types- cerebellar cortex(CRBL), frontal cortex(FCTX), hippocampus(HIPP), inferior
olivary nucleus(MEDU), occipital cortex(OCTX), pons(PONS), putamen(PUTM),
substantianigra(SNIG), temporal cortex(TCTX), thalamus(THAL), intralobular white
matter(WHMT).To get greater coverage of those Brain eSNPs in SEED GWAS, we
obtained proxy SNPs(r2 > 0.80, 1000 genome as reference panel) for the eSNPs not
found in SEED by using SNAP(http://archive.broadinstitute.org/mpg/snap/ldsearch.php).
Together with the proxy SNPs, we obtained a Brain eSNPs subset of 41,556 eSNPs,
as shown in the flow chart in Supplementary Figure 5.3.
5.2.3 Linkage disequilibrium(LD) pruning
We ran LD pruning by using the plink default method (variance inflation fac-
tor(VIF) with window size of 50, step size of 5 and VIF threshold at 2) for the brain
eSNP subset and brain tissue specific eSNP subsets(Supplementary Figure 5.3). The
final pruned brain eSNP subset contained 5,852 eSNPs in SEED. To make compa-
rable all LD-pruned SNP subsets in SEED, we used Priority Pruner on all SNPs in
SEED and with the pruned 5,852 eSNPs forced in Supplementary Figure 5.3. The
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brain tissue specific eSNPs in SEED are shown in Table 5.1.
In order to assess whether brain eQTL informed subsets improves our ability to de-
tect significant genetic variants, we compared the QQ plots between all pruned SNPs
vs. pruned brain eSNPs, in SEED, we ran similar LD pruning for all SNPs with the
5,852 pruned eSNPs forced in by using Priority Pruner (http://prioritypruner.sourceforge.net/)
with parameters equivalent to plink LD pruning (Supplementary Figure 5.3). A final
count of pruned SNPs is shown in Table 5.1.
5.2.4 SEED GWAS subsetting to brain eSNPs
We used the pruned subsets from Table 5.1 and applied them in SEED GWAS
analyses in plink (version 1.9) and R (version 3.3.1). QQ plots were examined for each
SNP subsets in order to see whether there are significant SNPs detected in the subset.
We calculated the adjusted significance level according to Bonferroni correction, and
listed the top SNP with the lowest p-value in each subset. Annotation of the SNP
and gene function is based on the NCBI databses dbSNP139 and RefSeq.140
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After Bonferroni correction, none of the SNPs in any SNP subsets exceeded the
corresponding adjusted significance level in SEED. However, among the temporal
cortex eSNPs from the SEED GWAS, the top eSNP (rs9876540, p = 8.8810−5) does
reach statistical significance, while for the rest of SNP subsets in SEED, the p-values
of top SNPs are about ten times greater than their adjusted significance level. Variant
rs9876540 is located in the intron region of gene CDCP1 according to dbSNP,139 and
CDCP1 is transmembrane protein that involves in regulation of celluar events by
RefSeq.140
5.3.2 Examining QQ-plots in SNP subsets of SEED
GWAS
In SEED, we compared the distribution of SNP p-values between all SNPs and
brain eSNPs, and before and after LD pruning in the QQ-plots in Figure 5.1. We
can clearly see that before pruning, there is significant deflation in both all SNPs and
brain eSNPs subset in SEED. After pruning, the deflation is greatly reduced, but
no apparent positive signals can be observed above the x=y line in Figures 5.1b and
5.1d. This is consistent with results from Table 5.1 that the top SNPs are far from
reaching statistical significance.
As for the brain region specific eSNP subsets in SEED, we also examined their QQ-
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5.4 Discussion
We found that in SEED, the QQ-plot of temporal cortex eSNP subsets showed
positive signal, and the top SNP rs9876540 in this subset almost reached the adjusted
significance level in this subset. These results suggest that ASD may affect the gene
expression in the temporal cortex or inferior olivary nucleus.
Our study reveals interesting findings in terms of possibly implicated brain re-
gions in ASD. Brain imaging studies have showed that the temporal cortex, which
plays a role in emotional regulation and social behavior,47might be affected in ASD
patients.141–144 However, there is currently no substantial evidence that the infe-
rior olivary nucleus is involved in ASD, though some studies implicate this region
in pediatric neurodegenerative disorders.145 We need further studies that assess the
association between structure or function of these brain regions and genetic profiles
among ASD patients and controls. One of the major limitations in this study is that
the brain eQTL studies often relied on a small sample of postmortem brains, and very
few brain samples are from prenatal and postnatal subjects. This limits our cover-
age of brain eSNPs that may involve in brain development. The other limitation is
that while LD pruning removes correlation between SNPs, possible significant signals
may be lost in this process. In general, integrating brain eQTLs in GWAS studies,
especially brain region eQTLs, can provide us some information on the etiology of
psychiatric disorders. Future brain eQTLs studies with more samples from prenatal






6.1 Summary of conclusions
The epigenetics analyses on injection drug use revealed that there are some CpG
sites that are suggestively associated with any injection drug use. The epigenetics
analyses on specific types of injection drug use showed that heroin only injection and
cocaine only injection lead to different epigenetics profiles changes. The joint analyses
on four kinds of injection drug use identified groups of CpG sites that are shared across
different injection drug use types, and these sites were enriched in immune response
pathways.
Similarly, the HIV epigenetic analyses have confirmed a previously reported gene
NLRC5 that was demethylated among chronic injection drug users. During the anal-
yses, we used a new method to specifically controls for the cell composition problem
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in HIV infection analyses. This analysis highlighted interesting genomic regions for
downstream biological analyses on understanding chronic HIV infection.
The genetics analyses on ASD have shown potential ways on integrating expression
data on brain into GWAS. With more data coming out on brain expression and larger
GWAS, we will be able to conduct better functional enrichment analyses in GWAS
and replicate our findings.
6.2 Future directions
With lowered cost on genotyping, sequencing and collection of epigenetic infor-
mation, it is possible to collect this type of data in on-going epidemiologic cohorts
and evaluate longitudinal changes on epigenetics data. It is both biologically inter-
esting and public health relevant whether the epigenome changes over time and how
much the changes accumulate at specific sites. We can evaluate both the epigenetic
differences between quitting after long-term injection, and relapse after quitting. We
treated these two injection status changes the same in our analyses, but they may
lead to different epigenetic outcomes. With a balanced design with epigenetic data
collected on injection, quitting, and relapse visits for every subject, we would be able
to distinguish these two types of injection status changes.
Based on the epigenetics results, we can try to develop predictive models that uti-
lize epigenetics information as biomarkers. The identified groups of CpG sites by the
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joint analyses may also contribute to better feature selection for developing predictive
models. We can use random forest to rank the importance of epigenetic features, and
select the most predictive markers to develop machine learning prediction models by
neural network, support vector machine, etc.
We would also test if there is overlap between methylation in the blood and brain
tissue since the addiction process happens in the brain. We have proposed to collect
epigenetics data on post-mortem brain tissue of opioid overdosed subjects to make
comparison between top CpG sites in the brain and blood.
Since HIV infection is perfectly correlated with cell composition in the blood,
alternatively, we can also do cell sorting first and then collect epigenetics data on
specific types of blood cells to avoid cell composition problems. We can target CD4+
cell and CD8+ cell specifically since the chronic HIV infection mostly affects these
two types of blood cells.
We can also improve our HIV analyses by measuring epigenetics data at the single
cell level. Since the HIV virus is randomly integrated into the human genome, it
might also affect the epigenome at the single cell level. We will be able to measure
the variability across CD4+ cells and it may provide important target sites for HIV
treatment.
Another important direction is that integrating genetics and expression data with
epigenetics data, and to try to find interesting genomic regions informed by the inte-
grated data. There are also other forms of functional genetics data, including histone
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modification, DNA hypersensitivity sites and ChIP-seq. It is equally important to
measure these types of data and integrate them with genetics and expression data.
Since the current brain eQTL database is established on about 100 brain tissues,
we would need to expand the brain expression database to obtain more brain eQTLs.
As long as the brain eQTLs and brain region specific eQTLs are well established, we
will be able to get a more accurate picture on whether brain eQTLs are enriched in
Autism Spectrum Disorder GWAS.
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C. Montiel-Nava, V. Patel, C. S. Paula, C. Wang et al., “Global prevalence of
autism and other pervasive developmental disorders,” Autism Research, vol. 5,
no. 3, pp. 160–179, 2012.
[50] T. A. Lavelle, M. C. Weinstein, J. P. Newhouse, K. Munir, K. A. Kuhlthau,
and L. A. Prosser, “Economic burden of childhood autism spectrum disorders,”
Pediatrics, vol. 133, no. 3, pp. e520–e529, 2014.
115
BIBLIOGRAPHY
[51] M. Stuart and J. H. McGrew, “Caregiver burden after receiving a diagnosis of
an autism spectrum disorder,” Research in Autism Spectrum Disorders, vol. 3,
no. 1, pp. 86–97, 2009.
[52] J. P. Leigh and J. Du, “Brief report: Forecasting the economic burden of autism
in 2015 and 2025 in the united states,” Journal of autism and developmental
disorders, vol. 45, no. 12, pp. 4135–4139, 2015.
[53] S. M. Myers, C. P. Johnson et al., “Management of children with autism spec-
trum disorders,” Pediatrics, vol. 120, no. 5, pp. 1162–1182, 2007.
[54] J. Hallmayer, S. Cleveland, A. Torres, J. Phillips, B. Cohen, T. Torigoe,
J. Miller, A. Fedele, J. Collins, K. Smith et al., “Genetic heritability and shared
environmental factors among twin pairs with autism,” Archives of general psy-
chiatry, vol. 68, no. 11, pp. 1095–1102, 2011.
[55] S. De Rubeis and J. D. Buxbaum, “Genetics and genomics of autism spectrum
disorder: embracing complexity,” Human molecular genetics, vol. 24, no. R1,
pp. R24–R31, 2015.
[56] S. Sandin, P. Lichtenstein, R. Kuja-Halkola, H. Larsson, C. M. Hultman, and
A. Reichenberg, “The familial risk of autism,” Jama, vol. 311, no. 17, pp. 1770–
1777, 2014.
[57] K. Wang, H. Zhang, D. Ma, M. Bucan, J. T. Glessner, B. S. Abrahams,
116
BIBLIOGRAPHY
D. Salyakina, M. Imielinski, J. P. Bradfield, P. M. Sleiman et al., “Common
genetic variants on 5p14. 1 associate with autism spectrum disorders,” Nature,
vol. 459, no. 7246, pp. 528–533, 2009.
[58] L. A. Weiss, D. E. Arking, M. J. Daly, A. Chakravarti, C. W. Brune, K. West,
A. OConnor, G. Hilton, R. L. Tomlinson, A. B. West et al., “A genome-wide
linkage and association scan reveals novel loci for autism,” Nature, vol. 461, no.
7265, pp. 802–808, 2009.
[59] R. Anney, L. Klei, D. Pinto, J. Almeida, E. Bacchelli, G. Baird, N. Bolshakova,
S. Bölte, P. F. Bolton, T. Bourgeron et al., “Individual common variants ex-
ert weak effects on the risk for autism spectrum disorders,” Human molecular
genetics, vol. 21, no. 21, pp. 4781–4792, 2012.
[60] A. Moreno-De-Luca, D. W. Evans, K. Boomer, E. Hanson, R. Bernier, R. P.
Goin-Kochel, S. M. Myers, T. D. Challman, D. Moreno-De-Luca, M. M. Slane
et al., “The role of parental cognitive, behavioral, and motor profiles in clinical
variability in individuals with chromosome 16p11. 2 deletions,” Jama psychia-
try, vol. 72, no. 2, pp. 119–126, 2015.
[61] E. B. Robinson, B. M. Neale, and S. E. Hyman, “Genetic research in autism
spectrum disorders,” Current opinion in pediatrics, vol. 27, no. 6, p. 685, 2015.
[62] C. A. Boyle, S. Boulet, L. A. Schieve, R. A. Cohen, S. J. Blumberg, M. Yeargin-
Allsopp, S. Visser, and M. D. Kogan, “Trends in the prevalence of developmental
117
BIBLIOGRAPHY
disabilities in us children, 1997–2008,” Pediatrics, vol. 127, no. 6, pp. 1034–1042,
2011.
[63] J. L. Matson and M. Shoemaker, “Intellectual disability and its relationship
to autism spectrum disorders,” Research in developmental disabilities, vol. 30,
no. 6, pp. 1107–1114, 2009.
[64] Y. Kim, K. Xia, R. Tao, P. Giusti-Rodriguez, V. Vladimirov, E. Van Den Oord,
and P. Sullivan, “A meta-analysis of gene expression quantitative trait loci in
brain,” Translational psychiatry, vol. 4, no. 10, p. e459, 2014.
[65] A. Ramasamy, D. Trabzuni, S. Guelfi, V. Varghese, C. Smith, R. Walker, T. De,
L. Coin, R. De Silva, M. R. Cookson et al., “Genetic variability in the regulation
of gene expression in ten regions of the human brain,” Nature neuroscience,
vol. 17, no. 10, pp. 1418–1428, 2014.
[66] D. L. Nicolae, E. Gamazon, W. Zhang, S. Duan, M. E. Dolan, and N. J. Cox,
“Trait-associated snps are more likely to be eqtls: annotation to enhance dis-
covery from gwas,” PLoS genetics, vol. 6, no. 4, p. e1000888, 2010.
[67] L. Chunyu, “Brain expression quantitative trait locus mapping informs genetic
studies of psychiatric diseases.”
[68] E. Courchesne, “Brain development in autism: early overgrowth followed by
118
BIBLIOGRAPHY
premature arrest of growth,” Developmental Disabilities Research Reviews,
vol. 10, no. 2, pp. 106–111, 2004.
[69] H. C. Hazlett, M. Poe, G. Gerig, R. G. Smith, J. Provenzale, A. Ross,
J. Gilmore, and J. Piven, “Magnetic resonance imaging and head circumfer-
ence study of brain size in autism: birth through age 2 years,” Archives of
general psychiatry, vol. 62, no. 12, pp. 1366–1376, 2005.
[70] B. M. Mathers, L. Degenhardt, B. Phillips, L. Wiessing, M. Hickman, S. A.
Strathdee, A. Wodak, S. Panda, M. Tyndall, A. Toufik et al., “Global epidemi-
ology of injecting drug use and hiv among people who inject drugs: a systematic
review,” The Lancet, vol. 372, no. 9651, pp. 1733–1745, 2008.
[71] G. M. Lucas, M. Griswold, K. A. Gebo, J. Keruly, R. E. Chaisson, and R. D.
Moore, “Illicit drug use and hiv-1 disease progression: a longitudinal study in
the era of highly active antiretroviral therapy,” American journal of epidemiol-
ogy, vol. 163, no. 5, pp. 412–420, 2006.
[72] S. A. Strathdee, T. B. Hallett, N. Bobrova, T. Rhodes, R. Booth, R. Abdool,
and C. A. Hankins, “Hiv and risk environment for injecting drug users: the
past, present, and future,” The Lancet, vol. 376, no. 9737, pp. 268–284, 2010.
[73] S. J. Blumberg, M. D. Bramlett, M. D. Kogan, L. A. Schieve, J. R. Jones, and
M. C. Lu, Changes in prevalence of parent-reported autism spectrum disorder
in school-aged US children: 2007 to 2011-2012. US Department of Health and
119
BIBLIOGRAPHY
Human Services, Centers for Disease Control and Prevention, National Center
for Health Statistics, 2013, no. 65.
[74] C. Gillberg, M. Cederlund, K. Lamberg, and L. Zeijlon, “Brief report:the autism
epidemic. the registered prevalence of autism in a swedish urban area,” Journal
of autism and developmental disorders, vol. 36, no. 3, p. 429, 2006.
[75] C. J. Newschaffer, M. D. Falb, and J. G. Gurney, “National autism prevalence
trends from united states special education data,” Pediatrics, vol. 115, no. 3,
pp. e277–e282, 2005.
[76] P. F. Sullivan, “The psychiatric gwas consortium: big science comes to psychi-
atry,” Neuron, vol. 68, no. 2, pp. 182–186, 2010.
[77] J. W. Ng, L. M. Barrett, A. Wong, D. Kuh, G. D. Smith, and C. L. Relton,
“The role of longitudinal cohort studies in epigenetic epidemiology: challenges
and opportunities,” Genome biology, vol. 13, no. 6, p. 246, 2012.
[78] J. Madrigano, A. A. Baccarelli, M. A. Mittleman, D. Sparrow, P. S. Vokonas,
L. Tarantini, and J. Schwartz, “Aging and epigenetics: longitudinal changes in
gene-specific dna methylation,” Epigenetics, vol. 7, no. 1, pp. 63–70, 2012.
[79] Y.-F. Chiu, A. E. Justice, and P. E. Melton, “Longitudinal analytical ap-
proaches to genetic data,” BMC genetics, vol. 17, no. 2, p. S4, 2016.
120
BIBLIOGRAPHY
[80] G. M. Fitzmaurice, N. M. Laird, and J. H. Ware, Applied longitudinal analysis.
John Wiley & Sons, 2012, vol. 998.
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